Advanced technology lenses work best in pristine eyes. Problems with ocular alignment, pupil size, ocular surface disease, irregular astigmatism, corneal dystrophies, scarring, and diseases of the ...
Phase 1b data show KSI-101 rapidly clears inflammatory macular edema, delivers long-lasting fluid control without steroids, ...
The results of a phase 1b study that evaluated a potential new treatment for macular edema associated with inflammation, ...
At Envision Summit 2026, the “Fast and Fundus” retina panel delivered rapid-fire case discussions grounded in practical ...
Ophthalmology Times, hosted by Douglas D. Koch, MD, Professor and Allen, Mosbacher, and Law Chair in Ophthalmology at the ...
Steffen Schmitz-Valckenberg, MD, discusses how optical coherence tomography-based models may enable rapid, noninvasive assessment of functional loss in GA at Angiogenesis 2026.
More recently established treatments for RVO have taken a giant leap forward from laser photocoagulation since intravitreally ...
In the United States, aflibercept-yszy received Food and Drug Administration (FDA) approval in May 2024 as a biosimilar to ...
Ocular Therapeutix has released positive topline results from SOL-1, its phase 3 superiority trial of AXPAXLI for the ...
A discussion of his situation led to the selection of the enVista Envy IOL. One month postoperatively, the patient achieved ...
According to recent data, patients initiating semaglutide had a substantially greater risk of developing NAION versus those starting SGLT2 inhibitors. Although rare, semaglutide initiation can lead to ...
Larissa Camejo, MD: I’m a glaucoma specialist and the owner of a solo private practice in Palm Beach Gardens, Florida. Our ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results